Articles scientifiques

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).

Auteurs : Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Huober J, Romagnoli D, Boccalini G, Vitale S, Sotiriou C, Biganzoli L, Di Leo A, Malorni L
Année : 2019
Journal : Ther Adv Med Oncol
Volume : 11
Pages : 1758835919891608

CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.

Auteurs : Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M
Année : 2019
Journal : Cell Rep
Volume : 29
Pages : 3405-3420.e5

Mammaprint™: a comprehensive review.

Auteurs : Brandão M, Pondé N, Piccart-Gebhart M
Année : 2019
Journal : Future Oncol
Volume : 15
Pages : 207-224

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Auteurs : Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothé F, Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J
Année : 2019
Journal : Nature
Volume : 571
Pages : 570-575

MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries.

Auteurs : Alexandri C, Stamatopoulos B, Rothé F, Bareche Y, Devos M, Demeestere I
Année : 2019
Journal : Sci Rep
Volume : 9
Pages : 9636

Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.

Auteurs : Matikas A, Zerdes I, Lövrot J, Richard F, Sotiriou C, Bergh J, Valachis A, Foukakis T
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 5717-5726

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Auteurs : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000515

SET_ER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.

Auteurs : Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 16

Denosumab in early-stage breast cancer.

Auteurs : Brandão M, Debiasi M, de Azambuja E
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : e234-e235

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Auteurs : Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, Von Minckwitz G, Bines J, Garg A
Année : 2019
Journal : Cancer Chemother Pharmacol
Volume : 83
Pages : 1147-1158

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Auteurs : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Année : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Auteurs : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Année : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Michael Dixon J, Piccart-Gebhart M, Sotiriou C
Année : 2019
Journal : PLoS One
Volume : 14
Pages : e0216175

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Auteurs : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

Tumor dormancy at bedside: A late awakening.

Auteurs : Demicheli R, Desmedt C, Piccart-Gebhart M, Biganzoli E
Année : 2019
Journal : Breast
Volume : 45
Pages : 61-63

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

Auteurs : Lambertini M, Richard F, Nguyen B, Viglietti G, Villarreal-Garza C
Année : 2019
Journal : Clin Med Insights Reprod Health
Volume : 13
Pages : 1179558119828393

Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.

Auteurs : Nguyen B, Veys I, Leduc S, Bareche Y, Majjaj S, Brown DN, Boeckx B, Lambrechts D, Sotiriou C, Larsimont D, Desmedt C
Année : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 742-746

ESR1 mutations in metastatic lobular breast cancer patients.

Auteurs : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 9

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Auteurs : Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 1434

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Auteurs : Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C
Année : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 25